top of page

BackTable / Urology / Podcast / Episode #26

Management of Small Renal Masses

with Dr. Phil Pierorazio

Dr. Phillip Pierorazio from Penn Urology discusses the management of small renal masses. Listen to the full episode to hear about imaging modalities for small renal masses, distinguishing between cysts and solid tumors, ablation, enucleation, partial nephrectomy, and special considerations for von Hippel-Landau (VHL) patients.

Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

Management of Small Renal Masses with Dr. Phil Pierorazio on the BackTable Urology Podcast)
Ep 26 Management of Small Renal Masses with Dr. Phil Pierorazio
00:00 / 01:04

BackTable, LLC (Producer). (2021, December 29). Ep. 26 – Management of Small Renal Masses [Audio podcast]. Retrieved from https://www.backtable.com

Free CME

Reflect on how this Podcast applies to your day-to-day and earn free AMA PRA Category 1 CMEs. Follow the button below to claim your credits on CMEfy.

BackTable CMEfy button

Stay Up To Date

Follow:

Subscribe:

Sign Up:

Podcast Contributors

Dr. Phil Pierorazio discusses Management of Small Renal Masses on the BackTable 26 Podcast

Dr. Phil Pierorazio

Dr. Phil Pierorazio is the chief of urology with the Pennsylvania Presbyterian Medical Center at the University of Pennsylvania.

Dr. Aditya Bagrodia discusses Management of Small Renal Masses on the BackTable 26 Podcast

Dr. Aditya Bagrodia

Dr. Aditya Bagrodia is an associate professor of urology and genitourinary oncology team leader at UC San Diego Health in California and adjunct professor of urology at UT Southwestern.

Show Notes

In this episode of BackTable Urology, Dr. Aditya Bagrodia and Dr. Phil Pierorazio discuss the management of small renal masses.

Most small renal masses found incidentally through imaging from another cancer workup or an injury, and most small renal masses are not cancer. It is important to take into account the patient’s family and social history, especially if there is a family history of renal cell carcinoma and renal disorders. Dr. Pierorazio looks specifically for flank pain, hematuria, and a history of smoking because these are all risk factors for cancerous small renal masses. In every patient, he orders a basic metabolic panel and a urodynamic analysis in order to observe renal function. Because CT scans are easily reproducible and interpreted, it is his first choice imaging modality. He also orders a chest x-ray, as pulmonary metastasis is common in renal cancer.

Active surveillance is a reasonable option once a small renal mass under 3 centimeters is discovered. Before deciding to put a patient on active surveillance as opposed to surgical intervention, Dr. Pierorazio assesses patient age, life expectancy and related comorbidities, and tumor size. However, tumors smaller than 3 centimeters should be removed if there is a possibility that the masses are caused by hereditary, aggressive cancers. High suspicion for these cancers should be raised in young women with a history of hysterectomies for fibroids. Another distinction that must be made is the difference between benign cysts and solid masses. Renal tumors are often not always completely solid, so they may masquerade as cysts. In order to improve the accuracy of the diagnosis, it is important to confirm the mass characteristics with multiple modalities.

A biopsy may be needed if the renal mass grows above 3 centimeters or if the patient is wanting more information. Additionally, a biopsy can help a surgeon decide whether a partial or radical nephrectomy is a better option. There are many different surgical options following the kidney biopsy: enucleation, nephrectomy, and ablation are three of the most common options. Surgical treatments can be sorted into two different types: partial nephrectomy and nephron-sparing options that maximize preservation of renal parenchyma. If a tumor is larger than 3 centimeters and well-encapsulated, Dr. Pierorazio favors enucleation. On the other hand, surgery may be contraindicated in older patients with multiple comorbidities because they are unlikely to progress to end-stage renal disease. For this reason, Dr. Pierorazio emphasizes the importance of listening to patients’ fears and desires, as both nephrectomy and dialysis can result in different risks and complications.

Resources

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

backtable-earn-free-cme.jpg
backtable-plus-vi-cta.jpg
Become a BackTable Sponsor

Up Next

The Terrible Urological 5: Time for Cystectomy & Urinary Diversion with Dr. Drew Peterson on the BackTable Urology Podcast)
The Evolution of Bladder Cancer Treatment: New Insights on Lymphadenectomy with Dr. Seth Paul Lerner on the BackTable Urology Podcast)
The Surgeon Scientist: Fostering the Next Generation with Dr. Ganesh Palapattu on the BackTable Urology Podcast)
The Genesis of Genitourinary Reconstruction Surgery (GURS) with Dr. Gerald Jordan on the BackTable Urology Podcast)
The Bladder Cancer Matters Podcast with Dr. Aditya Bagrodia and Rick Bangs on the BackTable Urology Podcast)
Perfecting Rectal Spacer Placement for Optimal Care with Dr. Neil Taunk on the BackTable Urology Podcast)

Articles

Topics

Kidney Cancer Condition Overview

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.

Select which show(s) you would like to subscribe to:

Thanks! Message sent.

bottom of page